Hallucinogens: LSD, Psilocybin, DMT and the Indolealkylamine Family

LSD on the illicit market is predominantly distributed on blotter paper, squares of absorbent paper (typically 6 mm x 6 mm) onto which a methanolic solution of LSD has been spotted and dried. Each square typically contains 50 to 200 micrograms of LSD (the 1960s-era Sandoz standard dose was 250 μg; modern blotters trend toward 75 to 100 μg). The paper substrate is commonly art paper or blotting paper printed with decorative motifs; a single sheet may contain 100, 225, or 900 individual squares perforated or scored for separation.

The analytical challenge begins with extraction. The drug must be removed from the paper matrix; LSD is soluble in methanol, ethanol, and chloroform. A single blotter square is extracted in 500 μL to 1 mL methanol by soaking and ultrasonication for 15 minutes. The extract is centrifuged, filtered through a 0.22 μm PTFE membrane, and injected. LSD is photolabile (it isomerises to iso-LSD under UV light within hours) and relatively thermolabile, so all steps are conducted under subdued illumination and at low temperatures.

Presumptive testing uses the Ehrlich reagent (p-dimethylaminobenzaldehyde in HCl/ethanol), which reacts with the indole nitrogen of LSD to produce a purple-violet colour. This test is highly sensitive but not specific to LSD alone; it responds to any indole-containing compound including other tryptamines, ergot alkaloids, and many pharmaceutical compounds.

Confirmation uses HPLC with fluorescence detection (HPLC-FLD). LSD is a strong natural fluorophore: excitation at 325 nm and emission at 445 nm. The fluorescence sensitivity achieves detection limits of approximately 1 to 10 picograms injected, making HPLC-FLD the most sensitive chromatographic method available without mass spectrometry. A C18 reverse-phase column (e.g. Waters Symmetry C18, 150 x 4.6 mm, 5 μm) with an acetonitrile-ammonium acetate mobile phase separates LSD from its degradation product iso-LSD and from common adulterants. For definitive identification, LC-MS/MS in positive ion mode provides the molecular ion ([M+H]+ at m/z 324) and characteristic product ions at m/z 223, 196, 179, and 156 that constitute the diagnostic fragmentation pattern. At 100 μg per blotter square, the drug is present at concentration readily confirmed; the challenge is the small physical quantity of material and the paper matrix, not the analytical sensitivity of the instrument.

The lysergamide family consists of LSD analogues in which the N,N-diethyl amide group is replaced by alternative amide substituents derived from lysergic acid. Like LSD, they bind the 5-HT2A serotonin receptor as partial agonists and produce LSD-like perceptual effects in humans. The major lysergamides encountered in forensic casework include:

LSZ (lysergic acid 2,4-dimethylazetidide), in which the diethylamine is replaced by a 2,4-dimethylazetidine ring. LSZ reportedly produces a longer-lasting and more potent effect than LSD per microgram, though clinical data are limited to anecdote and early microdosing trials.

AL-LAD (6-allyl-6-nor-lysergic acid diethylamide) differs from LSD at the N6 position of the ergoline ring, bearing an allyl group instead of methyl. It was first synthesised by Hofmann's group. It produces psychedelic effects qualitatively similar to LSD at comparable doses.

1P-LSD (1-propionyl-LSD) bears a propionyl group on the N1 position of the indole nitrogen. 1P-LSD is understood to act as a prodrug, with the propionyl group cleaved in vivo by esterases to release LSD; its subjective effects are described as virtually identical to LSD. 1P-LSD was sold legally in the UK and Germany from approximately 2014 until its scheduling in Germany (2019) and in the UK under the Psychoactive Substances Act 2016.

1cP-LSD (1-cyclopropionyl-LSD) and ETH-LAD followed as the next generation. Forensic identification of these compounds requires LC-MS/MS with reference standards; HPLC-FLD may detect the fluorescence signal (all lysergamides are similarly fluorescent) but cannot differentiate between LSD and its analogues without mass spectrometry.

The EMCDDA New Psychoactive Substances database listed 18 different lysergamide compounds as of December 2023. Most European jurisdictions that have a generic scheduling provision (such as the UK Psychoactive Substances Act 2016, which covers "any substance with a psychoactive effect" not specifically exempted) can prosecute lysergamide possession without naming the specific compound in a statutory instrument. The US Federal Analogue Act (21 USC 813) extends Schedule I controls to substances "substantially similar" to a Schedule I or II drug intended for human consumption, though its application to lysergamides has produced inconsistent case law.

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin (4-hydroxy-N,N-dimethyltryptamine) are the psychoactive compounds found in approximately 200 species of fungi, primarily in the genus Psilocybe, as well as in some species of Panaeolus, Copelandia, and Gymnopilus. The genus Psilocybe includes Psilocybe cubensis (the most widely cultivated), Psilocybe semilanceata (the liberty cap, common in UK and northern European grasslands), Psilocybe cyanescens (the wavy cap, found in wood-chip mulch in urban parks), and Psilocybe azurescens (a potent Pacific Northwest US species first described by Paul Stamets and Jochen Gartz in 1996).

The chemistry is structurally related to LSD: both share the tryptamine pharmacophore (indole ring with a 2-aminoethyl sidechain). Psilocybin is a phosphate ester prodrug. After ingestion, intestinal alkaline phosphatase dephosphorylates psilocybin to psilocin, which is the pharmacologically active compound. Psilocin itself rapidly oxidises in solution (producing the characteristic blue staining when mushroom tissue is broken, the blue bruising that identifies psilocybin-containing mushrooms in the field). The blue compound is a psilocin oxidation product (the quinoid form); the bruising reaction is used by mycologists as a presumptive field test.

Active doses are 1 to 4 mg of psilocybin (equivalent to approximately 1 to 2 g of dried Psilocybe cubensis, which contains roughly 0.5 to 1.0 per cent psilocybin by dry weight). Content varies considerably between species: Psilocybe azurescens and Psilocybe bohemica can contain up to 1.78 per cent and 1.34 per cent psilocybin respectively, while Panaeolus cyanescens may approach 1.0 per cent. These variations make dose estimation from seized dried mushroom weight imprecise without analytical quantification.

Forensic analytical workflow for psilocybin mushrooms uses HPLC-DAD (diode array detection) or LC-MS/MS. Psilocybin has UV absorption maxima at 267 and 320 nm; psilocin absorbs at 267 nm. Reversed-phase C18 HPLC with a phosphate-buffered mobile phase resolves psilocybin from psilocin and from the minor alkaloid baeocystin (4-phosphoryloxy-N-methyltryptamine). For species identification, morphological examination under stereomicroscopy (spore print colour and morphology, gill attachment, stipe characteristics) is combined with HPLC chemotaxonomy; DNA barcoding (ITS2 region) is increasingly used in reference laboratory casework for definitive species identification.

N,N-Dimethyltryptamine (DMT) is the simplest member of the tryptamine hallucinogen family: an indole with a dimethylaminoethyl sidechain, molecular formula C12H16N2, MW 188.27 g/mol. It is endogenous in humans (present in cerebrospinal fluid, blood, and pineal gland tissue in trace quantities) as well as in many plants including Psychotria viridis (chacruna, a shrub native to the Amazon Basin), Mimosa hostilis (jurema), and Acacia confusa. When smoked or vaporised (the freebase form, melting point 40-50°C, boiling point 160°C), a dose of 25 to 60 mg produces an intense, short-duration (10 to 20 minute) psychedelic experience. DMT is orally inactive because monoamine oxidase (MAO) in the gastrointestinal tract and liver rapidly deaminates it before it can reach systemic circulation.

This oral inactivity is overcome in ayahuasca by combining the DMT-containing plant with Banisteriopsis caapi vine (or other plants containing beta-carboline alkaloids: harmine, harmaline, and tetrahydroharmine). The beta-carbolines are reversible inhibitors of monoamine oxidase A (rMAO-A). By inhibiting intestinal and hepatic MAO, they allow orally ingested DMT to bypass first-pass metabolism, enter systemic circulation, and cross the blood-brain barrier. The interaction is a pharmacokinetic potentiation: harmine inhibits MAO-A at Ki approximately 0.1 μM, tetrahydroharmine inhibits serotonin re-uptake, and together they extend the duration of DMT's effect to 3 to 6 hours.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a more potent analogue of DMT, occurring naturally in the venom of Bufo alvarius (the Sonoran Desert toad, also called Incilius alvarius). The venom contains 5-MeO-DMT at approximately 15 per cent by dry weight. Dried toad venom is smoked in small quantities (1 to 5 mg active dose), producing an intense, brief psychedelic experience sometimes described as more overwhelming than DMT. 5-MeO-DMT is also found in several plant species (Anadenanthera peregrina, yopo snuff) and can be synthesised. It was added to the US Schedule I in January 2011 (Emergency Schedule) and placed in Schedule I by final rule in January 2012. EMCDDA documented 5-MeO-DMT in 10 EU member states as of 2022.

Forensic analysis of ayahuasca brew involves LC-MS/MS analysis of the complex mixture containing DMT, beta-carboline alkaloids, and plant-derived flavonoids. The beta-carbolines (harmine, harmaline, THH) are distinguished from DMT by retention time and accurate mass. DMT has [M+H]+ at m/z 189.14 (exact mass), with characteristic product ions at m/z 144 and 130. Harmine: [M+H]+ m/z 213.10. A validated HPLC method typically resolves all four principal alkaloids on a C18 column with acidified acetonitrile gradient, with UV detection at 254 nm supplemented by fluorescence detection.

The legal status of ayahuasca presents acute cross-jurisdictional complexity. In the US, the Supreme Court ruled in Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006) that the Religious Freedom Restoration Act (RFRA) protected a Brazilian religious organisation from prosecution under the Controlled Substances Act for importing ayahuasca for sacramental use. In the Netherlands, the Supreme Court ruled in 2019 that the União do Vegetal had no automatic RFRA-equivalent protection under Dutch law and that the DMT content of ayahuasca made it a List 1 prohibited substance regardless of religious context. In Brazil, ayahuasca for religious use has been explicitly legal since a CONAD resolution in 2010. In India, DMT is not specifically named in the NDPS Act schedules as of early 2024, though the Act's broad definition of psychotropic substances and the inclusion of tryptamines under amendment might apply.

The forensic chemistry implications of the psychedelic therapy wave are not purely academic. A forensic chemist receiving an exhibit of psilocybin capsules must now consider not just whether the substance is chemically confirmed as psilocybin, but whether it was produced within a licensed Oregon therapy framework (Measure 109, Oregon Health Authority licensing from 2023), an Australian TGA-authorised pharmaceutical context (Therapeutic Goods Administration Schedule 8 rescheduling effective July 2023), or an underground therapeutic context that remains clearly illegal.

In Oregon under Measure 109, licensed psilocybin service centres may possess and administer psilocybin mushroom products. The Oregon Health Authority's psilocybin programme rules (OAR Chapter 333) set specifications for psilocybin product manufacturing, testing (total psilocybin content by validated HPLC), and dispensing within licensed facilities. An exhibit seized outside a licensed facility, or from a person transporting product across state lines (still a federal violation), requires the same chemical confirmation: HPLC-DAD or LC-MS/MS quantification of psilocybin and psilocin content.

In Australia, the TGA's rescheduling (Delegate's final decision, February 2023, effective 1 July 2023) permits authorised psychiatrists to prescribe MDMA and psilocybin for specific therapeutic indications. The authorised prescriber pathway requires prior TGA approval for each patient. Forensic laboratories in Australia must now distinguish between pharmaceutical-context psilocybin (theoretically present in a licensed psychiatric practice) and illicit psilocybin. Packaging, GMP (good manufacturing practice) batch documentation, and chain-of-custody records determine this, not chemical identity alone.

At the federal level in the US, psilocybin and psilocin remain Schedule I (no accepted medical use, high abuse potential) under the Controlled Substances Act. The FDA's breakthrough therapy designations awarded to Compass Pathways (COMP360, synthetic psilocybin, for treatment-resistant depression) and USONA Institute (for major depressive disorder) do not alter Schedule I status; they only expedite the FDA review process for investigational new drug applications. Until the DEA formally rescheduled the compounds, FDA-approved Phase II/III clinical trials operate under Schedule I research exemptions (DEA Schedule I researcher registration, 21 CFR 1301.18).